301156 Shanghai Menon Animal Nutrition Technology
- 13.82
- +0.05+0.36%
Shanghai Menon Animal Nutrition Technology News
Meinong Biology (301156.SZ): Specializing in R&D, production and sales of feed additives and enzymolysis protein feed ingredients
Gelonghui, May 21丨Meinong Biotech (301156.SZ) said on the investor interactive platform that the company specializes in R&D, production and sales of feed additives and enzymolysis protein feed ingredients. The company always adheres to the business philosophy of “technology drives value, innovation drives development”, implements the customer value proposition of “product leadership, value service, partner growth”, and implements a “centralized differentiation” development strategy. At the product level, adhere to the product strategy of “classification and full nutrition”; at the market level, adhere to the market strategy of “deeply cultivating the domestic market and expanding overseas markets”, and continuously enhance the company's core competition with multiple strategies
Meinong Biotech (301156.SZ): It has now established a sales network in Brazil and other countries and regions
Gelonghui, May 14, 丨 Meinong Biotech (301156.SZ) recently said during a survey reception from institutional investors that the company has always been committed to exploring and developing the international market, and has laid a good foundation for the international market for more than 20 years. At present, the company has established sales networks in various countries and regions such as Vietnam, Russia, Thailand, Myanmar, the Philippines, Japan, South Korea, Pakistan, Bangladesh, Egypt, Jordan, Turkey, and Brazil. The company's future development plan for overseas business: (1) Following the country's “Belt and Road” policy, the company will focus on developing the Southeast Asian market, South Asia and the Middle East market. (2) At
Express News | Meinong Biotech invests in the establishment of an animal nutrition technology company
Express News | Meinong Biotech: The company's recent production and operation situation and internal and external business environment have not occurred or are expected to change significantly
Meinong Biotech (301156.SZ) plans to transfer 10 shares to 3 shares and distribute 5.5 yuan, excluding interest on May 13
Meinong Biotech (301156.SZ) announced that the company's 2023 equity distribution plan: 5.5 yuan (tax included) for every 10 shares to all shareholders; at the same time, the capital reserve fund will be used to transfer 3 shares for every 10 shares to all shareholders. The ex-dividend date is May 13, 2024.
Haili Wind Power (301156): Performance is under phased pressure, and the inflection point of the sea landscape recovery is imminent
Incident Company's 2023 Annual Report: The company's revenue in 2023 was 1,685 billion yuan, up 3.22% year on year; net profit loss to mother was 88 million yuan, down 143.0% year on year. The company's 2024 quarterly report:
Meinong Biotech (301156.SZ): Net profit of 9.58 million yuan in the first quarter increased 0.47% year-on-year
On April 24, Gelonghui Biotech (301156.SZ) released its first quarter report. Operating revenue was 97.906 million yuan, up 7.57% year on year, net profit of 9.58 million yuan, up 0.47% year on year, after deducting non-net profit of 8.979 million yuan, down 2.49% year on year, with basic earnings of 0.0856 yuan per share.
Meinong Biotech (301156.SZ): Products are currently mainly used in the fields of pigs, ruminants, poultry and aquatic products
On April 19, Ge Longhui (301156.SZ) held a performance briefing on April 19, 2024, to discuss “Does the company have any products for the pet market, and if so, what are the current plans? ”, the company replied that the company's products are currently mainly used in fields such as pigs, ruminants, poultry and aquatic products, and that the company currently receives pets such as couples and Forbes as representative customers. The company will promote corresponding business according to its own technological development and actual market demand.
Meinong Biotech (301156.SZ): Li Da plans to reduce its shares by no more than 1%
Gelonghui, April 18, 丨 Meinong Biotech (301156.SZ) announced that shareholder Li Da plans to reduce his holdings of the company's shares by no more than 1,107,281 shares (1% of the company's total share capital) through centralized bidding within 3 months after 15 trading days from the date of disclosure of this announcement.
Meinong Biotech (301156.SZ): A total cost of 1999.76 million yuan to buy back 1.1356% of the shares
Gelonghui, April 9, 丨 Meinong Biotech (301156.SZ) announced that as of April 9, 2024, the company had repurchased a total of 1,271,865 shares of the company through a special stock repurchase securities account, accounting for 1.1356% of the company's current share capital. The highest transaction price was 16.69 yuan/share, the minimum transaction price was 14.34 yuan/share, and the total transaction amount was 19,997,624.50 yuan (excluding transaction fees).
Meinong Biotech (301156.SZ): Net profit for 2023 increased by 20.10% to 63.0453 million yuan, plans to convert 10 to 3 to 5.5 yuan
Gelonghui, April 8 | Meinong Biotech (301156.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 504 million yuan, an increase of 4.37%; net profit attributable to shareholders of listed companies was 63.4053 million yuan, up 20.10% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 587.8861 million yuan, an increase of 16.93% year on year; basic income per share was 0.5629 yuan; it plans to distribute a cash dividend of 5.5 yuan (tax included) for every 10 shares to all shareholders, using capital reserves to the whole Shareholders will increase 3 shares for every 10 shares
Meinong Biotech (301156.SZ): Initial repurchase of 159,800 shares involving 2.321,400 yuan
Glonghui, March 13, 丨 Meinong Biotech (301156.SZ) announced that on March 13, 2024, for the first time, the company repurchased 1597.65 million shares of the company through a special stock repurchase securities account, accounting for 0.1426% of the company's total share capital. The highest transaction price was 14.75 yuan/share, the minimum transaction price was 14.34 yuan/share, and the total transaction amount was RMB 2,3214 million (excluding transaction fees).
Meinong Biotech (301156.SZ): It has established sales networks in dozens of countries including Vietnam, Russia, Myanmar, and the Philippines
Glonghui, Feb. 18 | Meinong Biotech (301156.SZ) said on the investor interactive platform that for many years, the company has been committed to exploring and developing the international market, and has laid a good foundation for the international market in early development. Currently, the company has established sales networks in dozens of countries including Vietnam, Russia, Myanmar, and the Philippines. Among them, the company developed the market in Vietnam early and has the highest sales share. In the future, the company will adhere to the market strategy of “deeply cultivating at home and expanding overseas” and continue to expand the international market along the “Belt and Road”.
Meinong Biotech (301156.SZ): Plans to spend 60 million yuan to 120 million yuan to buy back the company's shares
Gelonghui, Feb. 8, 丨 Meinong Biotech (301156.SZ) announced that the company plans to use its own funds to repurchase the company's shares through centralized bidding transactions, cancel them and reduce the company's registered capital accordingly; the total capital to repurchase shares shall not exceed RMB 120 million (inclusive), not less than RMB 60 million (inclusive); the repurchase price shall not exceed RMB 23.00 yuan/share (including the number of shares). The implementation period for share repurchase shall not exceed 12 months from the date the shareholders' meeting deliberates and approves the share repurchase plan. Based on the maximum repurchase price of 23.00 yuan/share, the estimated number of shares to be repurchased
Meinong Biotech (301156.SZ): The ban on 12.157,900 shares issued before the initial launch will be lifted on December 20
Glonghui, December 18|Meinong Biotech (301156.SZ) announced the lifting of restrictions on the sale of some shares issued before the initial public offering and the listing and circulation of some shares. The shares that have now been lifted are some of the company's issued shares before the initial public offering. The total number of shareholders whose sales restrictions were lifted this time was 3, and the number of shares lifted was 12.1578.94 million shares, accounting for 10.8553% of the company's total share capital. The listing date for the shares whose sale restrictions have been lifted is December 20, 2023 (Wednesday).
Meinong Biotech (301156.SZ) released results for the first three quarters, with net profit of 497.764 million yuan, an increase of 36.03% over the previous year
Meinong Biotech (301156.SZ) released its report for the third quarter of 2023. The company achieved operating income of 3 in the first three quarters...
Meinong Biotech (301156.SZ): Currently not involved in fish feed production
GLONGHUI, September 7: According to the Meinong Biotech (301156.SZ) investor relations activity record table, the company's overseas business is currently growing steadily. The company's overseas market business mainly covers more than 30 countries and regions, including Vietnam, Myanmar, Russia, Japan, South Korea, Spain, Peru, and Brazil. Currently, overseas business accounts for about 28% of the company's total business. In the future, the company will adhere to the market strategy of “deepening domestic expansion and overseas expansion”, and will further expand the international market along the “Belt and Road”. The company currently specializes in R&D, production and sales of feed additives and enzymolysed protein feed ingredients. It has not yet involved fish feeding
Meinong Biotech (301156.SZ) released first-half results, net profit of 2,5932 million yuan, an increase of 5.6%
Meinong Biotech (301156.SZ) released the 2023 semi-annual report. The company's revenue was 222 million...
Meinong Biotech (301156.SZ): In the pet market, it has now received representative customers such as Partners and Forbes
GLONGHUI August 16丨Some investors asked Meinong Biotech (301156.SZ), “Can you tell me more about your company's pet product development and promotion?” The company replied that the company specializes in R&D, production and sales of feed additives and enzymolysis protein feed ingredients. Currently, the company's products are mainly used in the fields of pigs, ruminants, poultry, and aquatic products. In the pet market, it has now received representative customers such as Partner and Phoebe. The company will promote corresponding business according to its own technological development and actual market demand.
Meinong Biotech (301156.SZ): Suzhou Meinong is currently still in the construction period of some production line equipment commissioning and gradual commissioning
Glonway, July 14丨Meinong Biotech (301156.SZ) recently said in response to a survey from institutional investors that Suzhou Meinong is currently still in the construction period of equipment commissioning and gradual commissioning of some production line equipment. The company will continue to strengthen coordination and make every effort to complete the construction of the project as soon as possible. This fund-raising project - “New Feed-related Product Production Project” - will add production capacity for acidity regulators and nutritional feed additives for ruminants. After the project is completed and put into operation, it will gradually expand the production capacity of acidity regulators and nutritional feed additives, which are the company's main business products, further increase the company's production scale and improve production efficiency
Analysis
Price Target
No Data
